报价延迟最少15分钟:2026/05/13 23:21 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.715 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.55/0.09
|
|
企业价值
1.41B
|
| 资产负债 |
|
每股账面净值
2.32
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
788.37M
|
|
每股收益
2.45
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA. |
